Related Experiment Videos
Coexpression of different antigenic markers on moieties that bear CA 125 determinants
Y H Yu1, D M Schlossman, C L Harrison
1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Cancer Research
|January 25, 1991
Summary
Investigating coexpression of ovarian cancer markers like CA 125 with other antigens, such as TAG 72, revealed significant heterogeneity. While coexpression offers potential specificity, current assays demonstrate reduced sensitivity for early ovarian cancer detection.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Background:
- CA 125 is a serum marker for epithelial ovarian carcinoma monitoring.
- Its utility for early detection is limited by benign conditions causing elevated levels.
- Coexpression of CA 125 with other tumor-associated epitopes may enhance specificity.
Purpose of the Study:
- To investigate the frequency of coexpression of CA 125 determinants with other tumor-associated antigens.
- To evaluate the potential of coexpression assays for improved ovarian cancer diagnosis.
Main Methods:
- Immunoaffinity chromatography to isolate CA 125+ moieties from ascites fluid.
- Western blotting and double determinant immunoradiometric assays using monoclonal antibodies (OC 125, NS 19-9, B72.3, DF3, OC 3632).
- Evaluation of serum samples from ovarian cancer patients and healthy individuals.
Main Results:
- Significant patient heterogeneity observed in coexpressed antigenic determinants with CA 125.
- Coexpression of TAG 72 and CA 125 was most frequent among tested combinations.
- The double determinant assay for TAG 72 and CA 125 coexpression was substantially less sensitive than individual antigen assays.
Conclusions:
- Coexpression of tumor-associated antigens with CA 125 shows marked heterogeneity in ovarian cancer.
- While potentially increasing specificity, current coexpression assays (e.g., TAG 72 and CA 125) exhibit reduced sensitivity compared to single marker assays.
- Further research is needed to develop sensitive and specific multi-antigen assays for early ovarian cancer detection.